Scholarlink

<p>This study aimed to explore the genotype-phenotype correlations in individuals with Genetic Skeletal Disorders (GSD), evaluate the efficacy of recombinant human Growth Hormone (rhGH) therapy. The retrospective analysis of the medical records of 80 pediatric patients with GSD diagnosed via whole-exome sequencing was conducted. The therapeutic effects of rhGH treatment were analyzed in 30 of these patients who received rhGH therapy. The study included 80 GSD patients, diagnosed at a median age of 4.88 years, with a median height standard deviation score (Ht-SDS) of −&#xa0;3.58. The most common clinical manifestations included skeletal deformities (87.5%), short stature (81.3%), and distinctive facial features (including triangular face, abnormality of the philtrum, abnormality of the forehead, etc.) (65.0%). A total of 33 pathogenic genes associated with 20 groups of GSD were identified. The most common groups are Type II collagenopathies (related to the <i>COL2A1</i> gene) (12/80, 15.0%) and the <i>FGFR3</i>-related chondrodysplasia group (12/80, 15.0%). Those with pathogenic genes linked to Fundamental Cellular Processes had more severe short stature and prenatal phenotypes. Thirty patients received rhGH treatment for a median of 2.25 years (0.33–8.92), showing Ht-SDS increases of 0.66 ± 0.42 and 0.84 ± 0.52, after one and two years, respectively (<i>p</i> &lt; 0.001). Eight untreated patients had an average Ht-SDS decrease of −&#xa0;0.46 ± 0.55. In this cohort, pediatric GSD patients predominantly presented with short stature, skeletal deformities, and distinctive facial features (including triangular face, abnormality of the philtrum, abnormality of the forehead, etc.), indicating a genotype-phenotype correlation. Compared to untreated GSD patients, those receiving rhGH treatment demonstrated varying degrees of height improvement, however, the long-term efficacy of this treatment warrants further investigation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Genetic skeletal disorders: phenotypic-genotypic characteristics and RhGH therapy responses of a pediatric cohort

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月1日

查看全文
  • Yiyun Huang,
  • Yan Peng,
  • Chuan Li,
  • Bobo Xie,
  • Xianda Wei,
  • Baoheng Gui,
  • Juan Meng,
  • Shaoke Chen,
  • Xin Fan

摘要

This study aimed to explore the genotype-phenotype correlations in individuals with Genetic Skeletal Disorders (GSD), evaluate the efficacy of recombinant human Growth Hormone (rhGH) therapy. The retrospective analysis of the medical records of 80 pediatric patients with GSD diagnosed via whole-exome sequencing was conducted. The therapeutic effects of rhGH treatment were analyzed in 30 of these patients who received rhGH therapy. The study included 80 GSD patients, diagnosed at a median age of 4.88 years, with a median height standard deviation score (Ht-SDS) of − 3.58. The most common clinical manifestations included skeletal deformities (87.5%), short stature (81.3%), and distinctive facial features (including triangular face, abnormality of the philtrum, abnormality of the forehead, etc.) (65.0%). A total of 33 pathogenic genes associated with 20 groups of GSD were identified. The most common groups are Type II collagenopathies (related to the COL2A1 gene) (12/80, 15.0%) and the FGFR3-related chondrodysplasia group (12/80, 15.0%). Those with pathogenic genes linked to Fundamental Cellular Processes had more severe short stature and prenatal phenotypes. Thirty patients received rhGH treatment for a median of 2.25 years (0.33–8.92), showing Ht-SDS increases of 0.66 ± 0.42 and 0.84 ± 0.52, after one and two years, respectively (p < 0.001). Eight untreated patients had an average Ht-SDS decrease of − 0.46 ± 0.55. In this cohort, pediatric GSD patients predominantly presented with short stature, skeletal deformities, and distinctive facial features (including triangular face, abnormality of the philtrum, abnormality of the forehead, etc.), indicating a genotype-phenotype correlation. Compared to untreated GSD patients, those receiving rhGH treatment demonstrated varying degrees of height improvement, however, the long-term efficacy of this treatment warrants further investigation.